Core Laboratories Inc. /DE/
For the period ended Mar 31, 2026. Filed May 1, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 1, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to the Interim Consolidated Financial Statements (Unaudited)
- DESCRIPTION OF BUSINESS
References to “Core Lab”, “Core Laboratories”, the “Company”, “we”, “our” and similar phrases are used throughout this Quarterly Report on Form 10-Q (“Quarterly Report”) and relate collectively to Core Laboratories Inc. and its consolidated subsidiaries.
We operate our business intwo segments: (1) Reservoir Description and (2) Production Enhancement. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields. For a description of the types of services and products offered by these operating segments, see Note 15 - Segment Reporting.
- SIGNIFICANT ACCOUNTING POLICIES UPDATE
Basis of Presentation and Principles of Consolidation
The accompanying unaudited interim consolidated financial statements include the accounts of Core Laboratories Inc. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP for the annual financial statements and should be read in conjunction with the audited financial statements and notes thereto included in Core Laboratories Inc.’s Annual Report on Form 10-K for the year ended December 31, 2025, including Note 2 -Summary of Significant Accounting Policies. Core Laboratories Inc.’s balance sheet information for the year ended December 31, 2025, was derived from the 2025 audited consolidated financial statements. There have been no changes to the accounting policies during the three months ended March 31, 2026, except as noted below.
Core Laboratories Inc. uses the equity method of accounting for investments in which it has less than a majority interest and does not exercise control but does exert significant influence. Non-controlling interest has been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned. All inter-company transactions and balances have been eliminated in consolidation.
In the opinion of management, all adjustments considered necessary for a fair statement of the results for the interim periods presented have been included in these financial statements. Furthermore, the operating results presented for the three months ended March 31, 2026, may not necessarily be indicative of the results that may be expected for the year ending December 31, 2026.
Certain reclassifications were made to prior period amounts included in this Quarterly Report on Form 10-Q in order to conform to the current period presentations. Refer to Core Laboratories Inc.’s Annual Report on Form 10-K for the year ended December 31, 2025, Note 2 -Summary of Significant Accounting Policies - Prior Period Immaterial Corrections. Specifically, the Company has made adjustments to previously reported beginning retained earnings and total assets for the three months ended March 31, 2025. These reclassifications had no impact on the reported net income or cash flows for the three months ended March 31, 2025.
Property, Plant and Equipment
We review our long-lived assets (“LLA”) for impairment when events or changes in circumstances indicate that their net book value may not be recovered over their remaining service lives. Indicators of possible impairment may include significant declines in activity levels in regions where specific assets or groups of assets are located, extended periods of idle use, declining revenue or cash flow or overall changes in general market conditions.
We have performed assessments for LLA located in regions impacted by the Middle East and Russia/Ukraine geopolitical conflicts and no triggering events have been identified to indicate that their net book value may not be recoverable as of March 31, 2026.
Recent Accounting Pronouncements
Pronouncements Adopted in 2026
In July 2025, FASB issued ASU 2025-05 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which allows public business entities to apply a practical expedient when estimating expected credit losses that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. The amendment is effective for annual and interim periods beginning after December 15, 2025. We adopted the guidance during the three months ended March 31, 2026. The Company has elected to apply the practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. When an account is determined to be uncollectible, we charge the receivable to our allowance for credit losses.
Issued But Not Yet Effective
In November 2024, FASB issued ASU 2024-03 Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40) to improve disclosures about a public business entity’s expenses, by providing more detailed information about the types of expenses in commonly presented expense captions. As amended by ASU 2025-01 issued in January 2025, the amendment is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendment may be applied prospectively or retrospectively. Upon adoption, our disclosures regarding expenses will be expanded.
In December 2025, FASB issued ASU 2025-11—Interim Reporting (Topic 270): Narrow-Scope Improvements to clarify the applicability of Topic 270, including types of interim reporting and the form and content of interim financial statements. It also provides a comprehensive list of required interim disclosures and requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendment is effective for interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. We do not expect the update to have an effect on our interim reporting.
- ACQUISITIONS AND DIVESTITURES
We hadno significant business acquisitions or divestitures during thethree months ended March 31, 2026 and 2025.
- INVENTORIES
Inventories consist of the following (in thousands):
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Finished goods | $27,201 | $24,962 |
| Parts and materials | 27,752 | 26,932 |
| Work in progress | 2,831 | 2,602 |
| Total inventories | $57,784 | $54,496 |
We include freight costs incurred for shipping inventory to our clients in the cost of product sales caption in the accompanying consolidated statements of operations.
- LEASES
Our operating leases primarily consist of offices and lab space, machinery, equipment, and vehicles. We terminated certain leases in the U.S. and other international locations during the three months ending March 31, 2026 and 2025. See Note 12 -Other (Income) Expense, net for additional information regarding lease termination costs.
The components of lease expense and other information are as follows (in thousands):
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Consolidated Statements of Operations: | ||
| Operating lease expense | $4,475 | $4,178 |
| Short-term lease expense | 411 | 489 |
| Variable lease expense | 479 | 481 |
| Total lease expense | $5,365 | $5,148 |
| Consolidated Statements of Cash Flows: | ||
| Operating cash flows - operating leases payments | $4,431 | $4,206 |
| Right of use assets obtained in exchange foroperating lease liabilities | $4,354 | $4,155 |
| Other information: | ||
| Weighted-average remaining lease term - operating leases | 7.72 years | 8.38 years |
| Weighted-average discount rate - operating leases | 5.42% | 5.46% |
Scheduled undiscounted lease payments for non-cancellable operating leases consist of the following (in thousands):
| Operating Leases | |
|---|---|
| Remainder of 2026 | $12,703 |
| 2027 | 11,257 |
| 2028 | 8,810 |
| 2029 | 6,145 |
| 2030 | 4,320 |
| Thereafter | 22,904 |
| Total undiscounted lease payments | 66,139 |
| Less: Imputed interest | (12,757) |
| Total operating lease liabilities | $53,382 |
- LONG-TERM DEBT, NET
We haveno finance lease obligations. Debt is summarized in the following table (in thousands):
| Interest Rate | Maturity Date | March 31,2026 | December 31,2025 | |
|---|---|---|---|---|
| Credit Facility - Revolving Loan | Variable | July 22, 2029 | $2,000 | $3,000 |
| Credit Facility - Delayed Draw Term Loan | Variable | July 22, 2029 | 50,000 | — |
| 2021 Senior Notes Series A (1) | 4.09% | January 12, 2026 | — | 45,000 |
| 2021 Senior Notes Series B (1) | 4.38% | January 12, 2028 | 15,000 | 15,000 |
| 2023 Senior Notes Series A (2) | 7.25% | June 28, 2028 | 25,000 | 25,000 |
| 2023 Senior Notes Series B (2) | 7.50% | June 28, 2030 | 25,000 | 25,000 |
| Total long-term debt | 117,000 | 113,000 | ||
| Less: Debt issuance costs | (2,540) | (2,745) | ||
| Long-term debt, net | $114,460 | $110,255 | ||
(1) Interest is payable semi-annually on June 30 and December 30.
(2)Interest is payable semi-annually on March 28 and September 28.
On July 22, 2025, we, along with our direct subsidiary Core Laboratories (U.S.) Interests Holdings, Inc. (“CLIH”) entered into the Ninth Amended and Restated Credit Agreement (as amended, the “Credit Facility”) for an aggregate borrowing commitment of $150.0 million with a $50.0 million “accordion” feature. Draws up to $100.0 million are available in the form of a revolving credit facility, and a single draw of $50.0 million was made in the form of a delayed draw term loan (“DDTL”) on January 12, 2026. The $50.0 million proceeds from the DDTL were primarily used to retire $45.0 million of Senior Notes Series A, which matured on January 12, 2026, see further discussion below. The DDTL is repayable in quarterly installments of $625 thousand beginning June 2026, and prepayments are permitted without penalty. We intend to repay the DDTL using borrowings under our existing long-term credit facility, therefore, we continue to classify this term loan as long-term debt. Any remaining outstanding balances under the revolving credit facility and the DDTL are due at maturity on July 22, 2029, subject to springing maturity dates unless the Company’s liquidity equals or exceeds the principal amount of each of the respective senior notes series that remain outstanding on each of the respective springing maturity dates as follows:
(1)
October 14, 2027, if any portion of the Company’s 2021 Senior Notes Series B due January 12, 2028, in the aggregate principal amount of $15.0 million, remains outstanding on October 14, 2027, and
(2)
March 30, 2028, if any portion of the Company’s 2023 Senior Notes Series A due June 28, 2028, in the aggregate principal amount of $25.0 million, remains outstanding on March 30, 2028.
The Credit Facility is secured by first priority interests in (1) substantially all of the tangible and intangible personal property, and equity interest of CLIH and certain of the Company’s U.S. and foreign subsidiary companies and (2) instruments evidencing intercompany indebtedness owing to the Company, CLIH and certain of the Company’s U.S. and foreign subsidiary companies. Certain of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes.
Under the Credit Facility, the Secured Overnight Financing Rate (“SOFR”) plus 2.00% to SOFR plus 3.00% will be applied to outstanding borrowings. The available capacity at any point in time is reduced by outstanding borrowings and outstanding letters of credit which totaled approximately $12.5 million at March 31, 2026, resulting in an available borrowing capacity under the Credit Facility of approximately $85.5 million. In addition to indebtedness under the Credit Facility, we had approximately $6.9 million of outstanding letters of credit and performance guarantees and bonds from other sources as of March 31, 2026.
The Credit Facility and Senior Notes include a cross-default provision, whereby a default under one agreement may trigger a default in the other agreements.
The terms of the Credit Facility and Senior Notes require us to meet certain covenants, including, but not limited to, an interest coverage ratio (calculated as consolidated EBITDA divided by interest expense) and a leverage ratio (calculated as consolidated net indebtedness divided by consolidated EBITDA), where consolidated EBITDA (as defined in each agreement) and interest expense are calculated using the most recent four fiscal quarters. The Credit Facility has more restrictive covenants with a minimum interest coverage ratio of 3.00 to 1.00 and permits a maximum leverage ratio of 2.50 to 1.00. The Credit Facility allows non-cash charges such as impairment of assets, stock compensation and other non-cash charges to be added back in the calculation of consolidated EBITDA. The terms of our Credit Facility also allow us to negotiate in good faith to amend any ratio or requirement to preserve the original intent of the agreement if any change in accounting principles would affect the computation of any financial ratio or covenant of the Credit Facility. In accordance with the terms of the Credit Facility, our leverage ratio is 1.20 and our interest coverage ratio is 7.20, each for the period ended March 31, 2026. We are in compliance with all covenants contained in our Credit Facility and Senior Notes as of March 31, 2026.
We, along with CLIH as issuer, have senior notes outstanding that were issued through private placement transactions. Series B of the 2021 Senior Notes were issued in 2021 (the “2021 Senior Notes”). Series A and Series B of the 2023 Senior Notes were issued in 2023 (the “2023 Senior Notes”). The 2021 Senior Notes and the 2023 Senior Notes are collectively the “Senior
Notes”. On January 12, 2026, we repaid the 2021 Senior Notes Series A with aggregate principal amount of $45.0 million upon the maturity date with the single draw of $50.0 million from the delayed draw term loan.
See Note 10 -Derivative Instruments and Hedging Activities for additional information regarding interest rate swap agreements we have entered to fix the underlying risk-free rate on our 2023 Senior Notes.
The estimated fair value of total debt at March 31, 2026 and December 31, 2025, approximated the book value of total debt. The fair value was estimated using Level 2 inputs by calculating the sum of the discounted future interest and principal payments through the maturity date.
- PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS
Prior to January 2020, one of our subsidiaries provided a noncontributory defined benefit pension plan covering substantially all of our Dutch employees who were hired prior to 2000 (“Dutch Plan”). This pension benefit was based on years of service and final pay or career average pay, depending on when the employee began participating. The Dutch Plan was curtailed prior to January 2020, and these employees have been moved into the Dutch defined contribution plan. However, the unconditional indexation for this group of participants continues for so long as they remain in active service with the Company.
The components of net periodic pension cost for the Dutch Plan include (in thousands):
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Interest cost | $423 | $347 |
| Expected return on plan assets | (350) | (280) |
| Net periodic pension cost | $73 | $67 |
- COMMITMENTS AND CONTINGENCIES
We have been and may, from time to time, be named as a defendant in legal actions that arise in the ordinary course of business. These include, but are not limited to, employment-related claims and contractual disputes or claims for personal injury or property damage which occur in connection with the provision of our services and products. A liability is accrued when a loss is both probable and can be reasonably estimated.
See Note 6 -Long-term Debt, net for amounts committed under letters of credit and performance guarantees and bonds.
- EQUITY
Treasury Stock
During the three months ended March 31, 2026, we distributed 4,670 shares of treasury stock upon vesting of stock-based awards. During thethree months ended March 31, 2026, we repurchased 51,781 shares of our common stock for $0.9 million, of which 1,695 shares valued at $29 thousand were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participant’s tax burdens resulting from the issuance of common stock under the plan. Such shares of common stock, unless canceled, may be reissued for a variety of purposes such as future acquisitions, non-employee director stock awards or employee stock awards.
Dividend Policy
In March 2026, we paid a quarterly cash dividend of $0.01 per share of common stock. In addition, on April 29, 2026, we declared a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on May 11, 2026, and payable on June 1, 2026.
Accumulated Other Comprehensive Income (Loss)
Amounts recognized, net of income tax, in accumulated other comprehensive income (loss) consist of the following (in thousands):
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Pension and other post-retirement benefit plans - unrecognized prior service costs and net actuarial loss | $(5,442) | $(5,499) |
| Interest rate swaps - net gain (loss) on fair value | (312) | (307) |
| Total accumulated other comprehensive income (loss) | $(5,754) | $(5,806) |
Retained Earnings
The beginning balances of retained earnings and total equity for the three months ended March 31, 2025 have been adjusted for certain prior period immaterial corrections. See Note 2 -Summary of Significant Accounting Policies Update.
- DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
We are exposed to market risks related to fluctuations in interest rates. To mitigate these risks, we may utilize derivative instruments in the form of interest rate swaps. We do not enter into derivative transactions for speculative purposes.
In March 2021, we entered into a forward interest rate swap agreement and carried the fair value of certain terminated variable-to-fixed swaps into the agreement in a “blend and extend” structured transaction. The purpose of this forward interest rate swap agreement was to fix the underlying risk-free rate, that would be associated with the anticipated issuance of new long-term debt by the Company in future periods. The forward interest rate swap would hedge the risk-free rate on forecasted long-term debt through March 2033. Risk associated with future changes in the 10-year LIBOR interest rates were fixed up to a notional amount of $60.0 million with this instrument. The interest rate swap qualified as a cash flow hedging instrument. The forward interest rate swap agreement was terminated and settled in April 2022. The hedging relationship was highly effective, therefore, the gain on the termination of the forward interest rate swap was included in accumulated other comprehensive income (loss). In June 2023, the Company issued the 2023 Senior Notes with an aggregate principal amount of $50.0 million at fixed interest rates of 7.25% and 7.50%. The Company has elected to apply the optional expedient for hedging relationships affected by reference rate reform. Accordingly, no outstanding balance on the 2023 Senior Notes will preclude cash flow hedging with the LIBOR hedging instrument. The unamortized net loss on this swap included in accumulated other comprehensive income (loss) at March 31, 2026 of $0.3 million will be amortized into interest expense in accordance with the forecasted transactions or the scheduled interest payments on the 2023 Senior Notes and any future debt through March 2033.
The effect of interest rate swaps on the consolidated statements of operations is as follows (in thousands):
| Three Months Ended | |||
|---|---|---|---|
| March 31, | |||
| 2026 | 2025 | Income Statement Classification | |
| Derivatives designated as hedges: | |||
| 5 year interest rate swap | $— | $(12) | Increase (decrease) to interest expense |
| 10 year interest rate swap | (6) | (208) | Increase (decrease) to interest expense |
| $(6) | $(220) | ||
- FINANCIAL INSTRUMENTS
The Company’s only financial assets and liabilities which are measured at fair value on a recurring basis relate to certain aspects of the Company’s benefit plans. We use the market approach to determine the fair value of these assets and liabilities using significant other observable inputs (Level 2) with the assistance of third-party specialists. We do not have any assets or liabilities measured at fair value on a recurring basis using quoted prices in an active market (Level 1) or significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the financial assets and liabilities are recorded in general and administrative expense in the consolidated statements of operations.
The following table summarizes the fair value balances (in thousands):
| Fair Value Measurement at | ||||
|---|---|---|---|---|
| Total | Level 1 | Level 2 | Level 3 | |
| Assets: | ||||
| Company owned life insurance policies (1) | $26,097 | $— | $26,097 | $— |
| $26,097 | $— | $26,097 | $— | |
| Liabilities: | ||||
| Deferred compensation liabilities | $18,565 | $— | $18,565 | $— |
| $18,565 | $— | $18,565 | $— | |
| Fair Value Measurement at | ||||
|---|---|---|---|---|
| Total | Level 1 | Level 2 | Level 3 | |
| Assets: | ||||
| Company owned life insurance policies (1) | $26,627 | $— | $26,627 | $— |
| $26,627 | $— | $26,627 | $— | |
| Liabilities: | ||||
| Deferred compensation liabilities | $18,451 | $— | $18,451 | $— |
| $18,451 | $— | $18,451 | $— | |
(1) Company owned life insurance policies have cash surrender value and are intended to assist in funding deferred compensation liabilities and other benefit plans.
- OTHER (INCOME) EXPENSE, NET
The components of other (income) expense, net, are as follows (in thousands):
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Gain on sale of assets | $(1,013) | $(6) |
| Results of non-consolidated subsidiaries | 79 | (37) |
| Foreign exchange (gain) loss, net | 380 | 480 |
| Rents and royalties | — | (7) |
| Return on pension assets and other pension costs | (350) | (280) |
| Assets write-down, loss on lease termination and other exit costs | 639 | 707 |
| Severance and other charges | — | 2,256 |
| Other, net | (380) | (778) |
| Total other (income) expense, net | $(645) | $2,335 |
During the three months ended March 31, 2026 and 2025, as a result of our continuous efforts in consolidating and exiting certain facilities in the U.S. and other international locations for operational efficiency, we sold property in Tulsa, Oklahoma for a net gain of $0.9 million. In addition, we recognized a write-down of the associated leasehold improvements, right of use assets and other assets and incurred lease termination and other exit costs of $0.6 million and $0.7 million, respectively.
Foreign exchange (gain) loss, net for the primary currencies in which we operate and those with a material effect for the period presented is summarized in the following table (in thousands):
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| British Pound | $(64) | $(6) |
| Canadian Dollar | 23 | 46 |
| Euro | (70) | 285 |
| Indonesian Rupiah | 50 | 74 |
| Russian Ruble | 97 | (185) |
| Other currencies, net | 344 | 266 |
| Foreign exchange (gain) loss, net | $380 | $480 |
- INCOME TAX EXPENSE (BENEFIT)
The Company recorded an income tax benefit of $(0.3) million for thethree months ended March 31, 2026 compared to income tax expense of $1.7 million for thethree months ended March 31, 2025. The effective tax rate for the three months ended March 31, 2026 and 2025, was 25.0% and 96.2%, respectively . The effective tax rate for thethree months ended March 31, 2026, was primarily impacted by the earnings mix of jurisdictions subject to tax for the period and items discrete to the quarter. The effective tax rate for the three months ended March 31, 2025, was impacted by approximately $1.4 million of additional tax expense recorded for items discrete to the quarter. These discrete items are primarily associated with the finalization of certain tax jurisdictions’ return to provision assessments due to changes in estimates.
- EARNINGS (LOSS) PER SHARE
We compute basic earnings (loss) per share by dividing net income (loss) attributable to Core Laboratories Inc. by the number of weighted average common shares outstanding during the period. Diluted earnings (loss) per share includes the incremental effect of contingently issuable shares from performance and restricted stock awards, as determined using the treasury stock method.
The following table summarizes the calculation of weighted average common shares outstanding used in the computation of basic and diluted earnings (loss) per share (in thousands):
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Weighted average common shares outstanding - basic | 46,073 | 46,773 |
| Effect of dilutive securities: | ||
| Restricted shares | — | — |
| Performance shares | — | — |
| Weighted average common shares outstanding - assuming dilution | 46,073 | 46,773 |
For the three months ended March 31, 2026 and 2025, the number of Core Laboratories Inc. restricted and performance shares of common stock that were excluded from the diluted earnings (loss) per share calculation as their impact would be antidilutive, were as follows (in thousands):
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Restricted shares | 89 | 77 |
| Performance shares | 887 | 730 |
- SEGMENT REPORTING
We operate our business intwo segments. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields.
Reservoir Description: Encompasses the characterization of petroleum reservoir rock and reservoir fluids samples to increase production and improve recovery of crude oil and natural gas from our clients’ reservoirs. We provide laboratory-based analytical and field services to characterize properties of crude oil and crude oil-derived products to the oil and gas industry. Services associated with these fluids include determining the quality and measuring the quantity of the reservoir fluids and their derived products, such as gasoline, diesel and biofuels. We also provide proprietary and joint industry studies based on these types of analyses and manufacture associated laboratory equipment. In addition, we provide reservoir description capabilities that support various activities associated with energy transition projects, including services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities around lithium and other elements necessary for energy storage.
Production Enhancement: Includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. We provide integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
We use the same accounting policies to prepare our operating segment results as are used to prepare our consolidated financial statements. All interest and other non-operating income (expense) is attributable to Corporate & Other and is not allocated to specific operating segments.
Our chief operating decision maker (“CODM”) is our Chief Executive Officer, who also serves as Chairman of the Board of Directors. The CODM uses revenue from unaffiliated clients and segment operating income to allocate resources, primarily for working capital, staffing and capital expenditures, during the annual budgeting process and monthly when comparing actual results to budgeted and forecasted results.
Summarized financial information of our operating segments is shown in the following table (in thousands):
| ReservoirDescription | ProductionEnhancement | Corporate &Other (1) | Consolidated | |
|---|---|---|---|---|
| CODM Measure - Revenue from unaffiliated clients | $81,931 | $39,866 | $— | $121,797 |
| Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | ||||
| Inter-segment revenue | 118 | 29 | (147) | — |
| Cost of services and product sales | 68,107 | 33,629 | 337 | 102,073 |
| General and administrative expense (2) | 9,970 | 4,748 | — | 14,718 |
| Depreciation and amortization | 2,779 | 985 | — | 3,764 |
| Other operating (income) expense, net (3) | (431) | (131) | (463) | (1,025) |
| Foreign exchange (gain) loss, net (3) | 478 | (140) | 42 | 380 |
| CODM Measure - Segment operating income | 1,146 | 804 | (63) | 1,887 |
| Supplemental Disclosures: | ||||
| Total assets | 333,341 | 141,142 | 113,245 | 587,728 |
| Capital expenditures | 4,509 | 306 | 76 | 4,891 |
| CODM Measure - Revenue from unaffiliated clients | $80,897 | $42,688 | $— | $123,585 |
| Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income: | ||||
| Inter-segment revenue | 16 | 68 | (84) | — |
| Cost of services and product sales | 64,605 | 34,761 | 103 | 99,469 |
| General and administrative expense (2) | 9,038 | 4,609 | — | 13,647 |
| Depreciation and amortization | 2,615 | 1,102 | — | 3,717 |
| Other operating (income) expense, net (3) | 2,128 | 539 | (812) | 1,855 |
| Foreign exchange (gain) loss, net (3) | 188 | 242 | 50 | 480 |
| CODM Measure - Segment operating income | 2,339 | 1,503 | 575 | 4,417 |
| Supplemental Disclosures: | ||||
| Total assets (4) | 318,436 | 149,297 | 118,510 | 586,243 |
| Capital expenditures | 2,422 | 1,129 | 28 | 3,579 |
(1) "Corporate & Other" represents those items that are not directly related to a particular operating segment and eliminations.
(2) General and administrative expense is presented as a total amount to the CODM and consists primarily of employee compensation costs, professional fees and information technology costs.
(3) Other operating (income) expense, net and foreign currency exchange (loss), net are included in the consolidated statement of operations as other (income) expense, net. See Note 12 - Other (income) expense, net for further details.
(4) Total assets at March 31, 2025 included in the Reservoir Description operating segment have been adjusted for certain prior period immaterial corrections. See Note 2 - Significant Accounting Policies Update.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.